NASDAQ OMX

Lindabs Building System (Astron) levererar byggnad till nytt Supernap datacenter i Italien

28.12.2015 16:15 | NASDAQ OMX

Dela

Lindabs Building System har erhållit en order att leverera en Astron-byggnad till Supernap till Milanoregionen i Italien med ett ordervärde på cirka 48 MSEK.

Supernaps nya datacenter kommer att bli ett "state-of-the-art" Tier IV Gold rankat datacenter som har designats för att uppnå högsta standard vad gäller säkerhet, hållbarhet och täthet för vatten. Byggnaden består bl a av ett ståltak med patenterad Switch SHIELD konstruktion inkluderande två oberoende takdäck som konstruerats för att klara extrema väderförhållanden och vindlaster upp till 200 mph. Underhåll och/eller utbyte av Switch SHIELD kan utföras när det är nödvändigt utan att påverka anläggningens kritiska aktiviteter.

Merparten av leveranserna äger rum under första halvåret 2016.

Lindabs VD och koncernchef Anders Berg kommenterar:

"Marknadsdiversifieringen inom Building Systems fortsätter och vi är glada att se en positiv utveckling för våra högkvalitativa prefabricerade Astronbyggnader både i västeuropa och på andra marknader. Dessa ansträngningar är viktiga för att kompensera för den minskade efterfrågan på våra ryska och vitryska marknader."

Slut

Informationen är sådan som Lindab International AB själv valt att offentliggöra eller är skyldig att offentliggöra enligt svensk lag om värdepappershandel och/eller lagen om Handel med Finansiella Instrument.

Kontakter:

LINDAB 
Anders Berg, VD och koncernchef
Email: anders.berg@lindab.com  
Mobil: +46 (0)70 35 89155

Fredrik Liedholm, chefsjurist
Email: fredrik.liedholm@lindab.com
Mobil: +46 (0)72 38 85742

Lindab - ventilations- och byggproduktföretag:

Lindab utvecklar, tillverkar, marknadsför och distribuerar produkter och systemlösningar för förenklat byggande och bättre inomhusklimat.

Produkterna kännetecknas av hög kvalitet, montagevänlighet, energi- och miljötänkande samt levereras med en hög servicegrad vilket sammantaget ger ett ökat kundvärde.

Koncernen omsatte 7 003 MSEK år 2014 och är etablerad i 35 länder med cirka 5 100 anställda. Huvudmarknaden är yrkesbyggnader som svarar för 80 procent av försäljningen medan bostäder står för 20 procent av försäljningen. Under 2014 stod den nordiska marknaden för 46 procent, CEE/CIS (Central- och Östeuropa samt övriga forna Sovjetstater) för 21 procent, Västeuropa för 30 procent och övriga marknader för 3 procent av den totala försäljningen.

Aktien är noterad på Nasdaq OMX Nordic Exchange, Stockholm, Mid Cap, under kortnamnet LIAB. Se även www.lindabgroup.com




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lindab International AB via Globenewswire

HUG#1975987

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressmeddelande

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressmeddelande

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum